

TB-Practecal Clinical Trial



- ✓ Aims to find **shorter, safer** more **effective** treatment for people living with drug-resistant tuberculosis (DR-TB).
- ✓ Evaluates the safety and efficacy of three **new drug regimens** compared to the World Health Organization (WHO) standard of care.

Belarus

Uzbekistan

South Africa

START

TRIAL LAUNCHED

JAN 2017 – DEC 2020

NOV 2020 – MAR 2021

MAR 2021

Stage 1

TB-Practecal

6 month
treatment regimens

All oral medication

- 1 Bedaquiline, Pretomanid and Linezolid + Moxifloxacin (BPaLM)
- 2 Bedaquiline, Pretomanid and Linezolid + Clofazimine (BPaLC)
- 3 Bedaquiline, Pretomanid and Linezolid (BPaL)

WHO

recommended
standard of care

9-24 months
treatment regimens

+/- injections

Stage 2

BPaLM proved
most effective
& safe, thereby
progressing to
Stage 2.

**Patient
enrolment
ends**

552 patients



**Data
analysis**

DEC 2022

OCT 2021

Trial ends + next steps



Médecins Sans Frontières, MSF, in collaboration with its partners, is committed to making shorter, safer and more effective DR-TB treatments, such as the TB-PRACTECAL regimens, available to patients more widely.

Results

Patients
cured

89%

Had side
effects

20%

Deaths

Zero

TB-Practecal - BPaLM

52%

59%

2

from TB or treatment
side effects

WHO standard of care

PRACTECAL 6-MONTH TREATMENT
BPaLM

More effective and safer
than WHO standard of care

PRACTECAL 6-MONTH TREATMENT
BPaL and BPaLC

Also proven to be effective
and safe for patients